Sensus Healthcare, Inc. (SRTS) Announces Q3 Loss While Exceeding Revenue Projections
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 07 2025
0mins
Source: NASDAQ.COM
Quarterly Performance: Sensus Healthcare reported a quarterly loss of $0.06 per share, better than the expected loss of $0.12, but down from earnings of $0.07 per share a year ago. The company also posted revenues of $6.88 million, exceeding estimates by 48.36%.
Stock Outlook: Despite the earnings surprise, Sensus Healthcare shares have declined by 46.7% this year, and the stock currently holds a Zacks Rank #4 (Sell), indicating expected underperformance in the near future.
Earnings Estimates: The consensus EPS estimate for the upcoming quarter is -$0.09 on revenues of $6.04 million, with a fiscal year estimate of -$0.43 on $26.34 million in revenues, reflecting an unfavorable trend in earnings estimate revisions.
Industry Context: The Medical - Instruments industry is currently ranked in the top 35% of Zacks industries, suggesting that overall industry performance could significantly influence Sensus Healthcare's stock performance moving forward.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SRTS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SRTS
Wall Street analysts forecast SRTS stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.820
Low
6.00
Averages
7.00
High
8.00
Current: 2.820
Low
6.00
Averages
7.00
High
8.00
About SRTS
Sensus Healthcare, Inc. is a medical device company. The Company is engaged in the development and delivery of non-invasive treatments for non-melanoma skin cancer (NMSC) and post-surgical keloid scar prevention. The Company uses a proprietary low-energy X-ray technology known as superficial radiation therapy (SRT), which is incorporated into a portfolio of treatment devices: the SRT-100, SRT-100+ and SRT-100 Vision. SRT technology is used to effectively and safely treat oncological and non-oncological skin conditions. The SRT-100 is a photon x-ray low-energy SRT system that provides patients with an alternative to surgery for treating NMSC, including basal cell and squamous cell skin cancers and other skin conditions such as keloids. The SRT-100 Vision provides the user with an SRT-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and comprehensive dosimetry parameters.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sensus Healthcare Reports Q1 2026 Earnings with Strategic Shifts
- Revenue Decline: Sensus Healthcare reported Q1 revenue of $3.4 million, down from $8.3 million year-over-year, primarily due to the absence of sales to its historically largest customer; however, excluding this customer, revenue increased to $2.7 million, indicating potential market recovery.
- Shipment Details: The company shipped 14 SRT systems during the quarter, including 10 direct sales and 4 placements under the Fair Deal Agreement, reflecting significant progress in broadening its customer base and reducing historical customer concentration.
- Profitability Goals: CEO Joseph Sardano reiterated the objective of achieving sustainable profitability in 2026, despite a decline in gross margin to 29.2% in Q1, primarily driven by product mix, indicating a need for strategic adjustments.
- Market Education and Adoption: Management emphasized that the new CPT codes effective January 2026 have led to positive initial reimbursement experiences, which are expected to drive customer adoption and revenue growth, particularly in dermatology applications.
See More
Sensus (SRTS) Q1 2026 Earnings Transcript
See More
Sensus Healthcare to Report Q1 2026 Financial Results on May 7, 2026
- Earnings Release Schedule: Sensus Healthcare will report its Q1 2026 financial results on May 7, 2026, with management hosting a conference call at 4:30 PM Eastern Time to review results and provide business updates, reflecting the company's commitment to transparency and investor communication.
- Conference Call Participation: Participants are encouraged to pre-register for a unique dial-in number to bypass the live operator, with pre-registration available anytime, including after the call starts, demonstrating the company's efforts to enhance investor engagement.
- International Dial-In Options: Those unable to pre-register can access the call by dialing 844-481-2811 (U.S. and Canada Toll-Free) or 412-317-0676 (International), ensuring global investor participation and enhancing the company's international communication capabilities.
- Innovation Background: Sensus Healthcare focuses on developing non-invasive treatments for skin cancer and keloids, leveraging its advanced superficial radiotherapy technology, showcasing the company's commitment to innovation in radiation oncology aimed at improving patient treatment experiences and clinical adaptability.
See More
New Financing Program Enhances Dermatology Equipment Acquisition
- Financing Program Launch: Sensus Healthcare has introduced a new financing service aimed at simplifying the acquisition process for dermatology practices seeking to purchase its superficial radiotherapy systems, thereby enhancing customer purchasing intent and market penetration.
- Conversion Rate Improvement: The new program is expected to improve the conversion rate of potential customers by reducing administrative and financing barriers, lowering the breakeven point to just one patient per month, which significantly alleviates the economic pressure of equipment procurement.
- Complementing Commercial Strategy: This financing service not only supports purchasing decisions for independent medical practices and corporate accounts but also strengthens relationships with physicians by providing financial visibility and reimbursement certainty, further solidifying Sensus' market position.
- Market Demand Response: With the new CPT codes providing approximately a 300% increase in per-fraction delivery codes for non-melanoma skin cancer treatment, Sensus' financing program will effectively support customer purchasing decisions in the new reimbursement environment, driving the company's growth in a rapidly evolving healthcare market.
See More
Sensus Healthcare Reports Q4 2025 Earnings with Positive Outlook
- New Coding Opportunities: Sensus Healthcare received exclusive CPT codes from CMS, ensuring clear reimbursement for non-melanoma skin cancer treatments, which after 16 years of effort provides the company with a fresh start and enhances confidence in non-invasive alternatives for physicians and patients.
- Improved Financial Performance: Q4 2025 revenues reached $4.9 million, up from $3.1 million in Q4 2024, despite a net loss of $3.2 million; however, the company ended the year with $22.1 million in cash, indicating strong financial health.
- International Market Expansion: Six systems were shipped to countries including China in Q4, positively impacting margins from international sales, highlighting the company's growth potential in global markets, particularly in the Asia-Pacific region.
- Optimistic Future Outlook: Management expects Q1 2026 system shipments to exceed Q4 levels, even without contributions from its largest customer, with a goal of achieving full-year profitability, reflecting confidence in market demand.
See More
Sensus Healthcare SRTS Q4 2025 Earnings Transcript
See More
Sensus Healthcare Reports Q1 2026 Earnings with Strategic Shifts
- Revenue Decline: Sensus Healthcare reported Q1 revenue of $3.4 million, down from $8.3 million year-over-year, primarily due to the absence of sales to its historically largest customer; however, excluding this customer, revenue increased to $2.7 million, indicating potential market recovery.
- Shipment Details: The company shipped 14 SRT systems during the quarter, including 10 direct sales and 4 placements under the Fair Deal Agreement, reflecting significant progress in broadening its customer base and reducing historical customer concentration.
- Profitability Goals: CEO Joseph Sardano reiterated the objective of achieving sustainable profitability in 2026, despite a decline in gross margin to 29.2% in Q1, primarily driven by product mix, indicating a need for strategic adjustments.
- Market Education and Adoption: Management emphasized that the new CPT codes effective January 2026 have led to positive initial reimbursement experiences, which are expected to drive customer adoption and revenue growth, particularly in dermatology applications.
See More
Sensus (SRTS) Q1 2026 Earnings Transcript
See More
Sensus Healthcare to Report Q1 2026 Financial Results on May 7, 2026
- Earnings Release Schedule: Sensus Healthcare will report its Q1 2026 financial results on May 7, 2026, with management hosting a conference call at 4:30 PM Eastern Time to review results and provide business updates, reflecting the company's commitment to transparency and investor communication.
- Conference Call Participation: Participants are encouraged to pre-register for a unique dial-in number to bypass the live operator, with pre-registration available anytime, including after the call starts, demonstrating the company's efforts to enhance investor engagement.
- International Dial-In Options: Those unable to pre-register can access the call by dialing 844-481-2811 (U.S. and Canada Toll-Free) or 412-317-0676 (International), ensuring global investor participation and enhancing the company's international communication capabilities.
- Innovation Background: Sensus Healthcare focuses on developing non-invasive treatments for skin cancer and keloids, leveraging its advanced superficial radiotherapy technology, showcasing the company's commitment to innovation in radiation oncology aimed at improving patient treatment experiences and clinical adaptability.
See More
New Financing Program Enhances Dermatology Equipment Acquisition
- Financing Program Launch: Sensus Healthcare has introduced a new financing service aimed at simplifying the acquisition process for dermatology practices seeking to purchase its superficial radiotherapy systems, thereby enhancing customer purchasing intent and market penetration.
- Conversion Rate Improvement: The new program is expected to improve the conversion rate of potential customers by reducing administrative and financing barriers, lowering the breakeven point to just one patient per month, which significantly alleviates the economic pressure of equipment procurement.
- Complementing Commercial Strategy: This financing service not only supports purchasing decisions for independent medical practices and corporate accounts but also strengthens relationships with physicians by providing financial visibility and reimbursement certainty, further solidifying Sensus' market position.
- Market Demand Response: With the new CPT codes providing approximately a 300% increase in per-fraction delivery codes for non-melanoma skin cancer treatment, Sensus' financing program will effectively support customer purchasing decisions in the new reimbursement environment, driving the company's growth in a rapidly evolving healthcare market.
See More
Sensus Healthcare Reports Q4 2025 Earnings with Positive Outlook
- New Coding Opportunities: Sensus Healthcare received exclusive CPT codes from CMS, ensuring clear reimbursement for non-melanoma skin cancer treatments, which after 16 years of effort provides the company with a fresh start and enhances confidence in non-invasive alternatives for physicians and patients.
- Improved Financial Performance: Q4 2025 revenues reached $4.9 million, up from $3.1 million in Q4 2024, despite a net loss of $3.2 million; however, the company ended the year with $22.1 million in cash, indicating strong financial health.
- International Market Expansion: Six systems were shipped to countries including China in Q4, positively impacting margins from international sales, highlighting the company's growth potential in global markets, particularly in the Asia-Pacific region.
- Optimistic Future Outlook: Management expects Q1 2026 system shipments to exceed Q4 levels, even without contributions from its largest customer, with a goal of achieving full-year profitability, reflecting confidence in market demand.
See More
Sensus Healthcare SRTS Q4 2025 Earnings Transcript
See More
